|
(a)(1) and (2). The response to this portion of Item 14 is submitted as a separate section of this report commencing on page F-1.
(b). On August 28, 2001 the Company filed a report dated August 27, 2001 on Form 8-K. The subject of the report was certain results of the Company’s U.S. Phase III clinical trial.
(c) and (a)(3). Exhibits are set forth on the following exhibit index.
(d). Not applicable.
|
|
|
|